Search ↗

Comparison

ARA-290 vs BPC-157

Both are healing & repair, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, ARA-290 is the better documented of the two (clinical trials). That is a statement about the state of the literature, not a recommendation.

ARA-290 BPC-157
Class Healing & repair Healing & repair
Evidence Clinical trials Animal models only
Human trials ~6 None published
Half-life ~2 minutes ~4 hours
Reported range 2-4 mg 200-500 mcg
Frequency Once daily 1-2x daily, often near the injury site
Routes Subcutaneous Subcutaneous, Oral, Intramuscular
FDA approved No No
Research use only Yes Yes
Banned in sport No Yes
Studied for Small fibre neuropathy, Neuropathic pain research, Tissue protection Tendon and ligament injury research, Gastrointestinal healing research, Soft tissue repair
Reported side effects Injection-site reactions, Headache, Fatigue Injection-site reactions, Transient nausea, Headache, Dizziness

ARA-290

ARA-290 corresponds to the helix-B surface region of erythropoietin, the portion that engages the innate repair receptor, a heteromer of the EPO receptor and the beta-common receptor. Because it does not bind the homodimeric EPO receptor that drives erythropoiesis, it delivers anti-inflammatory and neuroprotective signalling without raising haematocrit. Human trials in sarcoidosis-associated small fibre neuropathy reported improvements in neuropathic symptoms and corneal nerve fibre measures.

BPC-157

BPC-157 is a stable 15-amino-acid sequence derived from body protection compound, a protein found in human gastric juice. Animal work reports accelerated healing across tendon, ligament, muscle, bone and gastrointestinal tissue, with proposed mechanisms including upregulation of VEGF-driven angiogenesis, modulation of the nitric oxide system, and increased fibroblast migration and growth-factor receptor expression. The evidence base is almost entirely rodent. No adequately powered human trial has been published, which is the central fact about this compound and should lead every page about it.

ARA-290 vs BPC-157: common questions

What is the difference between ARA-290 and BPC-157?

Both are healing & repair. ARA-290: An 11-amino-acid erythropoietin derivative that keeps the tissue-protective signalling without any effect on red blood cell production. BPC-157: A synthetic pentadecapeptide derived from a gastric protein, and the most searched compound in the peptide category.

Which has stronger evidence, ARA-290 or BPC-157?

ARA-290 has the stronger evidence base (clinical trials, about 6 human studies) compared with BPC-157 (animal models only).

Are ARA-290 and BPC-157 FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 91810664) ↗ · structure, identifiers, synonyms
  2. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  3. PubChem compound record (CID 9941957) ↗ · structure, identifiers, synonyms
  4. WADA Prohibited List ↗ · current year
  5. CAS Registry Number 137525-51-0 ↗ · chemical identity

Published literature

  1. Rendell MS. The time to develop treatments for diabetic neuropathy.Expert Opin Investig Drugs 2021.PubMed 33423557 · doi:10.1080/13543784.2021.1868433
  2. van Velzen M, Heij L, Niesters M, et al.. ARA 290 for treatment of small fiber neuropathy in sarcoidosis.Expert Opin Investig Drugs 2014.PubMed 24555851 · doi:10.1517/13543784.2014.892072
  3. Atkins C, Wilson AM. Managing fatigue in sarcoidosis - A systematic review of the evidence.Chron Respir Dis 2017.PubMed 27507833 · doi:10.1177/1479972316661926
  4. Culver DA, Dahan A, Bajorunas D, et al.. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.Invest Ophthalmol Vis Sci 2017.PubMed 28475703 · doi:10.1167/iovs.16-21291
  5. Collino M, Thiemermann C, Cerami A, et al.. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.Pharmacol Ther 2015.PubMed 25728128 · doi:10.1016/j.pharmthera.2015.02.005
  6. Dahan A, Dunne A, Swartjes M, et al.. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.Mol Med 2013.PubMed 24136731 · doi:10.2119/molmed.2013.00122
  7. Luansritisakul C, Chiang MC, Burns SL, et al.. Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.Curr Pain Headache Rep 2026.PubMed 42635865 · doi:10.1007/s11916-026-01542-z
  8. Brines M, Dunne AN, van Velzen M, et al.. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Mol Med 2015.PubMed 25387363 · doi:10.2119/molmed.2014.00215
  9. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.Cell Tissue Res 2019.PubMed 30915550 · doi:10.1007/s00441-019-03016-8
  10. Seiwerth S, Rucman R, Turkovic B, et al.. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.Curr Pharm Des 2018.PubMed 29998800 · doi:10.2174/1381612824666180712110447
  11. Mayfield CK, Bolia IK, Feingold CL, et al.. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med 2026.PubMed 41476424 · doi:10.1177/03635465251357593
  12. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  13. DeFoor MT, Dekker TJ. Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?.Arthroscopy 2025.PubMed 39265666 · doi:10.1016/j.arthro.2024.09.005
  14. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  15. Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci 2026.PubMed 42123471 · doi:10.3390/ijms27093890
  16. Seiwerth S, Brcic L, Vuletic LB, et al.. BPC 157 and blood vessels.Curr Pharm Des 2014.PubMed 23782145 · doi:10.2174/13816128113199990421

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.